Som vedligeholdelsesbehandling hos patienter, som har opnået objektiv remission (mere end 50% reduktion i myeloid protein) efter initial induktionskemoterapi.
As maintenance therapy in patients who have achieved objective remission (more than 50% reduction in myeloma protein) following initial induction chemotherapy.